Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VKTX
#1456
Viking Therapeutics, Inc
35.5
2
USD
+1.46%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.46%
Monthly Change
+0.62%
6 month change
+5.65%
Year Change
+44.68%
Previous Close
35.0
1
Open
35.5
2
Bid
Ask
Low
35.5
2
High
35.5
2
Volume
94
Markets
US Stock Market
Healthcare
VKTX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
74.13 M
78.36 M
78.42 M
100.49 M
112.25 M
115.55 M
—
Valuation ratios
Enterprise value
388.25 M
334.1 M
631.49 M
1.78 B
4.49 B
3.9 B
12.39 B
Price to earnings ratio
-10.35
-6.46
-9.47
-20.09
-39.84
-11.03
-61.39
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
-18.77
-7.46
-13.53
-23.5
-49.98
-14.22
-66.61
Price to book ratio
1.67
1.76
4.5
4.95
4.98
6.2
8.71
Enterprise value to EBITDA ratio
—
—
—
-16.34
-26.7
-9.68
-46.75
Profitability ratios
Return on assets %
-0.15
-0.26
-0.41
-0.23
-0.12
-0.5
-0.47
Return on equity %
-0.16
-0.27
-0.47
-0.25
-0.12
-0.56
-0.51
Return on invested capital %
-11.89 K
-50 K
-28.78 K
-23.85 K
-37.93 K
-169 K
-163.15 K
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
21.12
23.98
7.61
19.19
33.09
9.33
107.78
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.3
-0.62
-0.63
-0.78
-0.81
-2.47
-2.48
EBIT per share
-0.59
-0.72
-0.92
-1.07
-1.38
-3.49
-3.5
EBITDA per share
—
—
—
-1.16
-1.54
-3.57
-3.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
3.42
2.62
2.02
3.84
8.28
6.26
27.43
Net current asset value per share
3.53
2.73
2.17
3.89
8.32
6.35
28.03
Tangible book value per share
3.37
2.62
1.89
3.69
8.07
5.67
26.67
Working capital per share
3.36
2.61
1.89
3.69
8.07
5.67
26.66
Book value per share
3.37
2.62
1.89
3.69
8.07
5.67
26.67
News
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?